NCT00961467View on ClinicalTrials.gov

RMPT for Relapsed/Refractory Multiple Myeloma

PHASE2CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

February 28, 2007

Primary Completion Date

March 31, 2008

Study Completion Date

April 30, 2016

Conditions
Multiple Myeloma
Interventions
DRUG

Revlimid, Melphalan, Prednisone, Thalidomide

Thalidomide was administered at 50 mg/day.

DRUG

Revlimid, Melphalan, Prednisone, Thalidomide

Thalidomide was administered at 100 mg/day.

Trial Locations (1)

10126

Azienda Ospedaliera S Giovanni Battista, Torino

All Listed Sponsors
lead

Fondazione EMN Italy Onlus

OTHER

NCT00961467 - RMPT for Relapsed/Refractory Multiple Myeloma | Biotech Hunter | Biotech Hunter